<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04919655</url>
  </required_header>
  <id_info>
    <org_study_id>RECHMPL21_0086</org_study_id>
    <nct_id>NCT04919655</nct_id>
  </id_info>
  <brief_title>Primary Lymphedema and Mutation CELSR1 (Cadherin EGF LAG Seven-pass G-type Receptor 1)</brief_title>
  <acronym>CELSR1</acronym>
  <official_title>Clinical and Functional Expression Associated With CELSR1 Mutations in Primary Lymphedema of Lower Limbs</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Montpellier</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>GEHU - Duve Institute - Bruxelles</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Montpellier</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators will describe the expression of mutation CELSR1 with codon stop and amino&#xD;
      acids substitution mechanism in primary lymphedema, in both clinical examination and imaging&#xD;
      exploration&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      According to the literature, it seems that the mutation of the CELSR1 gene is associated with&#xD;
      primary lymphedema.&#xD;
&#xD;
      Thus, the investigators have identified families with CELSR1 mutation with codon stop or&#xD;
      animo acid substitution mechanisms among patients followed up in vascular medicine&#xD;
      department, at Montpellier University hospital for primary lymphedema of lower limbs.&#xD;
&#xD;
      Among the mutation carriers, the investigators have collected the clinical examinations and&#xD;
      imaging exploration results, realized systematically during the follow up of all the patient&#xD;
      with primary lymphedema (venous Doppler, MRI of the lymphatic system, lymphoscintigraphy of&#xD;
      the lower limbs, abdominal ultrasound), in order to search for a morphological and functional&#xD;
      pattern associated with the mutation.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 1, 2021</start_date>
  <completion_date type="Anticipated">February 20, 2022</completion_date>
  <primary_completion_date type="Anticipated">February 1, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Presence of unilateral lymphedema of lower limbs</measure>
    <time_frame>day 1</time_frame>
    <description>Describe the clinical examination of all CELSR1 mutation carriers: with ISL classification and perimeter measurement and Stemmer sign.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>type of the morphological and functional pattern with imaging exploration.</measure>
    <time_frame>day 1</time_frame>
    <description>Describe the morphological and functional pattern of the CELSR1 mutation with the imaging exploration</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>determine if deactivator mutation of CELSR1</measure>
    <time_frame>day 1</time_frame>
    <description>determine if deactivator mutation of CELSR1 is associated with :&#xD;
Great saphenous vein anatomical variation&#xD;
kidney's anomalies</description>
  </secondary_outcome>
  <enrollment type="Anticipated">31</enrollment>
  <condition>Primary Lymphedema</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with primary lymphedema of lower limbs, which carriewho carry d the codon stop or&#xD;
        the amino acids substitution CELSR1 mutation, followed up at Montpellier University&#xD;
        Hospital regardless of the age.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
          -  Patient followed up in vascular medicine departement at Montpellier University&#xD;
             Hospital for primary lymphedema of lower limbs, who carries the CELSR1 mutation with&#xD;
             codon stop or amino acids substitution mechanism.&#xD;
&#xD;
          -  Relatives to the index case who carry the mutation for the segregation study.&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  Patients who carry another mutation than CELSR1 responsible for primary lymphedema&#xD;
&#xD;
          -  Syndromic form of primary lymphedema&#xD;
&#xD;
          -  Patient not followed up at Montpellier University Hospital.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>MESTRE GODIN Sandrine</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Montpellier</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>MESTRE GODIN Sandrine, MD, PhD</last_name>
    <phone>467337028</phone>
    <phone_ext>33</phone_ext>
    <email>s-mestre@chu-montpellier.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Aurélie LAY, résident</last_name>
    <phone>4 67 33 70 28</phone>
    <phone_ext>33</phone_ext>
    <email>a-lay@chu-montpellier.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Uhmontpellier</name>
      <address>
        <city>Montpellier</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>MESTRE GODIN Sandrine</last_name>
      <phone>467337028</phone>
      <phone_ext>33</phone_ext>
      <email>s-mestre@chu-montpellier.fr</email>
    </contact>
    <contact_backup>
      <last_name>Stéphanie BADOUAILLE</last_name>
      <phone>4 67 33 70 28</phone>
      <phone_ext>33</phone_ext>
    </contact_backup>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>March 18, 2021</study_first_submitted>
  <study_first_submitted_qc>June 2, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 9, 2021</study_first_posted>
  <last_update_submitted>June 2, 2021</last_update_submitted>
  <last_update_submitted_qc>June 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>CELSR1</keyword>
  <keyword>primary lymphedema of lower limbs</keyword>
  <keyword>lymphedema</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphedema</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>NC</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

